Bio-Rad Laboratories, Inc. reports results for the quarter ended September 30 - Earnings Summary

What happened

Bio-Rad Laboratories reported adjusted earnings of $2.65 per share for the quarter ended September 30, up from $2.26 a year earlier and above analysts’ $2.23 expectation. Revenue increased 0.5% to $656.40 million, exceeding the $649.95 million forecast.

Confirmed

Global impact / market context

Earnings and revenue both topped the stated analyst expectations, which may support confidence in the company’s ability to generate sales and profit. However, revenue growth was modest, so continued results will matter for judging whether earnings strength is durable.

Analyst inference

The context is mixed: shares were up 23.7% so far this year but down 0.7% this quarter. Analysts’ average rating was hold, and their median 12-month price target was below the last closing price.

Analyst inference

What to watch

1. Watch upcoming revenue and adjusted earnings reports to see whether the 0.5% sales increase continues and whether earnings remain above analyst expectations. Proposed
2. Analysts had made no earnings-estimate revisions in the previous 30 days, while their average estimate had declined about 0.3% over three months. Confirmed
3. The average analyst rating was hold, and its $362.50 target sat about 4.8% below the $379.99 last close; changes could signal revised expectations. Analyst inference

Evidence

• Original source link unavailable